Baird has initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) Inc with an 'outperform' rating and a $10 price target. In a note to clients, Baird's ...

Analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a ...

The average one-year price target for TRACON Pharmaceuticals (NASDAQ:TCON) has been revised to 6.63 / share. This is an increase of 21.88% from the prior estimate of 5.44 dated October 4, 2023.

StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research report report published on Tuesday morning.